Chardan Capital Reaffirms Buy Rating for Silence Therapeutics (NASDAQ:SLN)
Chardan Capital reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a report issued on Friday,Benzinga reports. Chardan Capital currently has a $35.00 price target on the stock. Several other brokerages have also recently issued reports on SLN. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective […]
Chardan Capital reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a report issued on Friday,Benzinga reports. Chardan Capital currently has a $35.00 price target on the stock. Several other brokerages have also recently issued reports on SLN. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective […]
